Dihydropyrimidinone positive modulation of delta-subunit-containing gamma-aminobutyric acid type A receptors, including an epilepsy-linked mutant variant.
Gamma-aminobutyric acid type A receptors (GABA(A) receptors) are ligand-gated chloride channels that play a central role in signal transmission within the mammalian central nervous system. Compounds that modulate specific GABA(A) receptor subtypes containing the delta-subunit are scarce but would be valuable research tools and starting points for potential therapeutic agents. Here we report a class of dihydropyrimidinone (DHPM) heterocycles that preferentially potentiate peak currents of recombinant GABA(A) receptor subtypes containing the delta-subunit expressed in HEK293T cells. Using the three-component Biginelli reaction, 13 DHPMs with structural features similar to those of the barbiturate phenobarbital were synthesized; one DHPM used (monastrol) is commercially available. An up to approximately 3-fold increase in the current from recombinant alpha1beta2delta receptors was observed with the DHPM compound JM-II-43A or monastrol when co-applied with saturating GABA concentrations, similar to the current potentiation observed with the nonselective potentiating compounds phenobarbital and tracazolate. No agonist activity was observed for the DHPMs at the concentrations tested. A kinetic model was used in conjunction with dose-dependent measurements to calculate apparent dissociation constant values for JM-II-43A (400 muM) and monastrol (200 microM) at saturating GABA concentrations. We examined recombinant receptors composed of combinations of subunits alpha1, alpha4, alpha5, alpha6, beta2, beta3, gamma2L, and delta with JM-II-43A to demonstrate the preference for potentiation of delta-subunit-containing receptors. Lastly, reduced currents from receptors containing the mutated delta(E177A) subunit, described by Dibbens et al. [(2004) Hum. Mol. Genet. 13, 1315-1319] as a heritable susceptibility allele for generalized epilepsy with febrile seizures plus, are also potentiated by these DHPMs.
Lewis
Ryan W
RW
Department of Molecular Biology and Genetics, Biotechnology Building, Cornell University, Ithaca, New York 14853-2703, USA.
Mabry
John
J
Polisar
Jason G
JG
Eagen
Kyle P
KP
Ganem
Bruce
B
Hess
George P
GP
D000409:Alanine / Q000235:genetics; D000494:Allosteric Regulation / Q000235:genetics; D002460:Cell Line; D004357:Drug Synergism; D004827:Epilepsy / Q000235:genetics* / Q000378:metabolism*; D014644:Genetic Variation; D018698:Glutamic Acid / Q000235:genetics; D006801:Humans; D016297:Mutagenesis, Site-Directed; D011485:Protein Binding / Q000187:drug effects; D020033:Protein Isoforms / Q000235:genetics / Q000378:metabolism; D021122:Protein Subunits / Q000378:metabolism*; D011743:Pyrimidines / Q000494:pharmacology; D011744:Pyrimidinones / Q000494:pharmacology*; D011963:Receptors, GABA-A / Q000235:genetics* / Q000378:metabolism*; D013871:Thiones / Q000494:pharmacology
C546240:GABRA1 protein, human; D020033:Protein Isoforms; D021122:Protein Subunits; D011743:Pyrimidines; D011744:Pyrimidinones; D011963:Receptors, GABA-A; D013871:Thiones; D018698:Glutamic Acid; C400223:monastrol; D000409:Alanine
Proc Natl Acad Sci U S A. 1987 Dec;84(24):8758-62
2447583
BMC Chem Biol. 2006 Feb 27;6:2
16504166
Epilepsy Curr. 2009 Jan-Feb;9(1):18-23
19396344
J Recept Signal Transduct Res. 2006;26(5-6):731-40
17118808
J Physiol. 2007 Jun 15;581(Pt 3):1001-18
17395622
J Neurosci. 2006 Feb 1;26(5):1499-506
16452673
Annu Rev Biophys Biophys Chem. 1987;16:507-34
2439099
Alcohol. 2007 May;41(3):145-53
17521846
J Gen Physiol. 1997 Mar;109(3):401-14
9089445
J Pharmacol Exp Ther. 2006 Mar;316(3):1351-9
16272218
Mol Pharmacol. 2002 Apr;61(4):861-9
11901225
Nat Neurosci. 2007 Jan;10(1):40-8
17159992
J Med Chem. 1990 Sep;33(9):2629-35
2391701
J Biol Chem. 2009 Mar 20;284(12):7889-96
19141615
J Physiol. 1957 Aug 29;138(1):63-80
13463799
Handb Exp Pharmacol. 2008;(182):31-51
18175085
Neuropharmacology. 2009 Jan;56(1):182-9
18762200
Neuropharmacology. 2009 Jan;56(1):141-8
18760291
J Physiol. 1996 Dec 1;497 ( Pt 2):509-22
8961191
Epilepsia. 2002;43 Suppl 5:3-8
12121286
J Neurosci. 1998 Mar 1;18(5):1693-703
9464994
Nat Rev Drug Discov. 2007 Mar;6(3):189-201
17330070
Biochem Pharmacol. 2004 Oct 15;68(8):1497-506
15451392
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15218-23
14625373
Neuropharmacology. 2005 Sep;49(3):300-16
15993433
Alcohol. 2007 May;41(3):155-62
17521845
Nat Genet. 2001 May;28(1):46-8
11326274
Epilepsia. 2002;43 Suppl 6:21-5
12190974
Biochemistry. 2004 Jun 15;43(23):7534-40
15182195
Neurotherapeutics. 2007 Jan;4(1):18-61
17199015
Biochemistry. 1992 Jun 23;31(24):5477-87
1377021
J Med Chem. 1989 Oct;32(10):2399-406
2552119
Eur J Pharmacol. 2006 Jul 17;541(3):158-62
16777089
Curr Opin Pharmacol. 2006 Feb;6(1):18-23
16376150
Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301
7638184
Nat Neurosci. 2002 Aug;5(8):721-2
12118257
J Physiol. 1999 Jan 1;514 ( Pt 1):27-45
9831714
Expert Opin Investig Drugs. 2005 May;14(5):601-18
15926867
Pharmacol Ther. 1996;69(3):173-98
8783370
Br J Pharmacol. 2008 Mar;153(5):1062-71
18204487
J Neurosci. 2002 Mar 1;22(5):1541-9
11880484
Neuropharmacology. 2009 Jan;56(1):155-60
18778723
Biochemistry. 2006 Sep 26;45(38):11632-41
16981722
Int J Biochem Cell Biol. 2006;38(8):1254-76
16520081
J Physiol. 2001 Dec 15;537(Pt 3):715-33
11744750
Proc Natl Acad Sci U S A. 1980 Feb;77(2):842-6
6928684
Pflugers Arch. 1981 Aug;391(2):85-100
6270629
J Comb Chem. 2004 Nov-Dec;6(6):884-92
15530114
Toxicol Lett. 1998 Nov 23;100-101:217-24
10049145
J Neurosci. 2008 May 14;28(20):5383-93
18480294
J Neurosci. 2003 Nov 26;23(34):10934-43
14645489
Adv Pharmacol. 2006;54:231-63
17175817
J Neurosci. 1994 Nov;14(11 Pt 2):7077-86
7525894
Hum Mol Genet. 2004 Jul 1;13(13):1315-9
15115768
Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217
10209232
J Cell Biol. 2000 Sep 4;150(5):975-88
10973989
J Neurosci. 1998 Jul 1;18(13):4993-5007
9634565
Eur J Med Chem. 2000 Dec;35(12):1043-52
11248403
Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12905-10
10536021
Adv Biochem Psychopharmacol. 1995;48:41-56
7653325
Neuroscience. 2000;101(4):815-50
11113332